Mecapegfilgrastim for Prevention of Chemotherapy-Induced Neutropenia in Advanced Breast Cancer

Authors
Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2026
This prospective, real-world observational registry study will evaluate the effectiveness and safety of mecapegfilgrastim for the prevention of chemotherapy-induced neutropenia in patients with advanced breast cancer receiving chemotherapy. The decision to use mecapegfilgrastim will be made by the treating physician as part of routine clinical care. Participants will be followed to collect information on neutropenia, febrile neutropenia, treatment-related adverse events, and chemotherapy delivery.
Epistemonikos ID: 222a78ba82d9472675016ddbf5fa210179123d58
First added on: Oct 28, 2026